Austrianova’s CEO and CTO will be attending the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), which will be held from June 3-7 in Chicago. Austrianova’s partner, PharmaCyte, will host a medical and scientific discussion of its therapy for pancreatic cancer among top oncologist investigators during the ASCO meeting. The Cell-in-a-Box® technology and the pancreatic cancer clinical trial design will be discussed at the meeting with a panel of clinicians, including those who will be involved in the trial and the PharmaCyte management team.
